HC Wainwright Issues Optimistic Forecast for TARA Earnings

Protara Therapeutics, Inc. (NASDAQ:TARA) – Equities researchers at HC Wainwright raised their Q2 2026 earnings estimates for shares of Protara Therapeutics in a report issued on Wednesday, May 13th. HC Wainwright analyst A. Maldonado now forecasts that the company will post earnings per share of ($0.31) for the quarter, up from their previous forecast of ($0.40). HC Wainwright has a “Buy” rating and a $27.00 price target on the stock. The consensus estimate for Protara Therapeutics’ current full-year earnings is ($1.48) per share. HC Wainwright also issued estimates for Protara Therapeutics’ Q3 2026 earnings at ($0.31) EPS, Q4 2026 earnings at ($0.31) EPS, FY2026 earnings at ($1.24) EPS, FY2027 earnings at ($1.37) EPS, FY2028 earnings at ($0.34) EPS, FY2029 earnings at $0.60 EPS and FY2030 earnings at $1.10 EPS.

Other equities analysts have also recently issued research reports about the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Protara Therapeutics in a research note on Tuesday, April 21st. Wall Street Zen raised shares of Protara Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday. JPMorgan Chase & Co. lowered their target price on shares of Protara Therapeutics from $27.00 to $26.00 and set an “overweight” rating on the stock in a research note on Thursday, May 14th. Finally, TD Cowen reissued a “buy” rating on shares of Protara Therapeutics in a research note on Tuesday, March 10th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $24.50.

Protara Therapeutics Trading Down 9.8%

Protara Therapeutics stock opened at $4.60 on Tuesday. The stock has a market cap of $258.52 million, a price-to-earnings ratio of -3.43 and a beta of 1.53. The company’s 50-day moving average price is $5.24 and its two-hundred day moving average price is $5.70. Protara Therapeutics has a 52 week low of $2.77 and a 52 week high of $7.82.

Protara Therapeutics (NASDAQ:TARA) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($0.31) earnings per share for the quarter, beating the consensus estimate of ($0.36) by $0.05.

Insider Activity

In other news, insider Jacqueline Zummo sold 22,598 shares of Protara Therapeutics stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $5.26, for a total value of $118,865.48. Following the transaction, the insider owned 95,961 shares of the company’s stock, valued at $504,754.86. The trade was a 19.06% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 7.60% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Protara Therapeutics

Several hedge funds have recently made changes to their positions in TARA. JPMorgan Chase & Co. purchased a new position in shares of Protara Therapeutics in the second quarter worth approximately $46,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new stake in shares of Protara Therapeutics in the 2nd quarter valued at approximately $53,000. Persistent Asset Partners Ltd purchased a new stake in shares of Protara Therapeutics in the 4th quarter valued at approximately $57,000. AXQ Capital LP purchased a new stake in shares of Protara Therapeutics in the 4th quarter valued at approximately $58,000. Finally, The Manufacturers Life Insurance Company purchased a new stake in shares of Protara Therapeutics in the 4th quarter valued at approximately $59,000. Institutional investors and hedge funds own 38.13% of the company’s stock.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for virus-driven cancers. The company’s primary areas of research include human papillomavirus (HPV)–associated malignancies, where it seeks to harness and enhance the body’s immune response to target tumor cells. Protara’s therapeutic strategy combines antigen-specific vaccination approaches with modulators of T-cell activation to improve clinical outcomes in patients with HPV-mediated disease.

Protara’s lead immunotherapy candidate is PTX-35, an investigational monoclonal antibody designed to agonize OX40, a co-stimulatory receptor on T cells.